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PENILAIAN DASAR, FAKTOR PENENTU DAN CIRI-CIRI KEMASUKAN 
UBAT GENERIK KE DALAM PASARAN FARMASEUTIKAL MALAYSIA
ABSTRAK
Sistem penjagaan kesihatan Malaysia bergantung ke atas ketersediaan ubat-ubatan
generik yang setara dengan ubat-ubatan inovasi untuk mengurangkan perbelanjaan
farmaseutikal yang semakin meningkat. Kajian ini menilai dimensi dan dinamik
kemasukan ubat generik berikutan tamat paten pada produk-produk ubat inovasi di 
Malaysia. Ini adalah kajian kaedah-bercampur. Hasil kajian ini menunjukkan 14 
kategori dasar-dasar dan langkah-langkah pengawalan dengan kesan berbeza-beza ke
atas kemasukan generik di Malaysia. Kaji selidik melalui mel menghasilkan kadar
respons yang boleh digunakan sebanyak 53.8% (14/26) berikutan empat mel berturut-
turut. Pekali kebolehpercayaan pembolehubah keputusan kemasukan pelbagai item dan
halangan kemasukan adalah 0.62 dan 0.82 masing-masing. Faktor-faktor utama yang 
memacu pembangunan generik dan keputusan kemasukan di Malaysia adalah pra-paten 
nilai pasaran tamat produk inovasi itu (Min-pangkat=3.75, M=4.14, SD=1.03), kos
pembangunan generik dan kelulusan (Min-pangkat=3.04, M=3.50, SD=1.40) dan
keserasian ubat generik baru dengan pelbagai produk firma yang sedia ada (Min-
pangkat=2.79, M=3.64, SD=1.2). Pra-paten tamat nilai pasaran produk inovasi ini
adalah factor kemasukan yang signifikan untuk firma-firma generik berorientasikan
pasaran domestik berbanding dengan firma yang berorientasikan pasaran eksport (U= 
0.00, Z=-2.36, p=0.01). Halangan utama kepada pembangunan ubat-ubatan generik dan
kemasukan pasaran di Malaysia adalah kelompok paten oleh firma inovasi (Min-
pangkat=7.96, M=4.07, SD=0.83) dan kemasukan awal ke dalam pasaran bagi ubat-
xxiii
ubatan generik yang diimport (Min-pangkat=7.75, M=4.07, SD=0.73). Dasar-dasar dan
peraturan-peraturan kerajaan dilihat sebagai agak berkesan dalam mempromosikan
ubat-ubatan generik di Malaysia. Majoriti daripada responden, 64.3% dan 69.2% 
masing-masing tidak berpuas hati dengan aktiviti mempreskripsi ubat generik dan
pendidikan dan pemberian maklumat ubat-ubatan generik kepada professional 
penjagaan kesihatan. Separuh daripada responden tidak puas hati dengan kesedaran 
orang awam terhadap ubat generik. Majoriti daripada responden (57.1%) berpuas hati
dengan pendispensan ubat generik di Malaysia. Dalam kajian ini, sejumlah 154 
kemasukan ubat generik (M=12.83, SD=9.61) yang berlaku selama tempoh data 8 tahun
bagi seluruh 12 sampel ubat dan proses kemasukan dicirikan dengan tren garis 
melengkuk kuadratik berurutan (sequential quadratic curvilinear trend) yang signifikan 
(R2=0.83, p=<0.001). Masa kemasukan (dalam hari) ubat generik adalah jelas lewat
melampaui masa kemasukan satu hari sepertimana yang dihipotesiskan selepas tamat
tempoh paten asas produk inovator (median=125, M=396.92, SD=507.49, Z=-2.284, 
p=0.02). Analisis sekunder persaingan generik dalam kalangan 28 ubat-ubatan yang 
tamat paten yang mana majority telah berada dalam pasaran untuk beberapa tahun
menunjukkan peningkatan ketersediaan ubat generik telah menurunkan keseluruhan
harga ubat dalam pasaran farmaseutikal tamat paten. Dapatan kajian ini menunjukkan
kepentingan kemasukan bilangan ubat generik yang cukup dan memastikan tanpa
halangan selepas tamat paten produk-produk ubat inovator. Secara keseluruhan, kajian 
ini mendedahkan kehadiran pelbagai dasar dengan pelbagai kesan ke atas kemasukan 
ubat-ubatan generik di Malaysia. Kemasukan ubat-ubatan generik di Malaysia didapati 
ditentukan oleh nilai jualan pra-paten produk inovator, kos pembangunan generik, 
xxiv
persaingan kemasukan pasaran dan kewujudan halangan kemasukan berkaitan dengan 
paten. Sekiranya berlaku kemasukan, corak kemasukan generik dicirikan oleh satu trend 
garis melengkung berurutan, tetapi masa untuk kemasukan generik didapati 
ditangguhkan dengan ketara selepas tarikh habis tempoh paten asas ke atas produk 
inovasi di Malaysia.
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ASSESSMENT OF POLICIES, DETERMINANTS AND CHARACTERISTICS 
OF GENERIC MEDICINES ENTRY INTO THE MALAYSIAN 
PHARMACEUTICAL MARKET
ABSTRACT
The Malaysia healthcare system relies on the availability of generic equivalents of 
innovator medicines to curtail the rising pharmaceutical expenditure. This study 
assesses the dimensions and dynamics of generic medicines entry following patent 
expiration on the innovator drug products in Malaysia. This was a mixed-methods 
study. The findings of this research revealed 14 categories of policies and regulatory 
measures with varying effects on generic entry in Malaysia. The mail survey yielded a 
usable response rate of 53.8% (14/26) following four successive mailings. Reliability 
coefficients for the multi-item entry decisions and entry barriers variables were 0.62 and 
0.82 respectively. The major factors driving generic development and entry decisions in 
Malaysia were pre-patent expiration market value of innovator’s products (Mean-
rank=3.75, M=4.14, SD=1.03), cost of generic development and approval (Mean-rank= 
3.04,  M=3.50, SD=1.40) and compatibility of the new generic medicine with firms’ 
existing products range (Mean-rank=2.79,  M=3.64, SD=1.2). The innovator product’s 
pre-patent expiration market value was a significant entry driver for domestic-market 
oriented generic firms as compared with export-market oriented firms (U=0.00, Z=-
2.36, p=0.01). The Major barriers to generic medicines development and market entry 
in Malaysia were patent clustering by innovator firms (Mean-rank=7.96, M=4.07, 
SD=0.83) and earlier market entry of imported generics (Mean-rank=7.75, M=4.07, 
SD=0.73). Government policies and regulations were perceived to be fairly effective in 
xxvi
promoting generic medicines in Malaysia. Majority of the respondents, 64.3% and 
69.2% were dissatisfied with generic prescribing and generic medicines education and 
information to healthcare professionals respectively. A majority of the respondents 
(57.1%) were satisfied with generic dispensing in Malaysia. In this study, a total 154 
generic entries (M=12.83, SD=9.61) occurred over an 8-year data period for the entire 
12 drug sample, and entry occurrence is significantly characterized by a sequential 
quadratic curvilinear trend (R2=0.83, p=<0.001). The time to entry (in days) of generic 
entrants is significantly delayed beyond the hypothesized time to entry of one day 
following basic patent expiration on innovator products (Mdn=125, M=396.92, 
SD=507.49, Z = -2.284, p=0.02). Secondary analysis of generic competition among the 
28 off-patent drugs, majority of which have been in the market for several years shows 
that increased generics availability reduces the overall drug price in the off-patent 
pharmaceutical market, a finding that illustrates the importance of ensuring unhindered 
and sufficient entry of generic medicines following patent expiration on the innovator 
drug products. Overall, this research revealed the presence of a variety of policies with 
varying effects on the entry of generic medicines in Malaysia. The entry of generic 
medicines in Malaysia was found to be determined by the pre-patent sales value of the 
innovator products, cost of generic development, market entry competition and the 
existence patent-related entry barriers. In the event of entry, the pattern of generic entry 
is characterized by a sequential curvilinear trend, but the time to generic entry is found 
to be significantly delayed beyond the date of basic patent expiration on innovator 
product in Malaysia.
1CHAPTER 1
GENERAL INTRODUCTION
1.1 Background
The rising pharmaceutical expenditure in many countries around the world, including 
Malaysia, has led governments and non-governmental health organizations to advocate 
the use of generic medicines (World Health Organization [WHO], 2001; De Joncheere, 
Rietveld and Huttin, 2002; Ford, 2004; Kanavos, Costa-Font and Seeley, 2008; Ministry
of Health [MOH], Malaysia, 2009a). A generic medicine is a “pharmaceutical product, 
usually intended to be interchangeable with the innovator product, which is usually 
manufactured without a license from the innovator company and marketed after the 
expiry of patented or other exclusivity rights” (WHO, 2011, p.41); and innovator
product “is generally that which first was authorized for marketing on the basis of 
documentation of efficacy, safety and quality” (WHO, 2011, p.41).
However, because generic medicines typically incur comparatively lower 
developmental costs, they are offered at a lower price (Reiffen and Ward, 2005; 
Simoens, 2009; Brems, Seville and Baeyens, 2011). Thus, generic medicines play a key 
role in ensuring drug affordability and containment of pharmaceutical costs, since the 
prices of medicines on the market is a major component of pharmaceutical expenditure 
(Ess, Schneeweiss and Szucs, 2003; Dukes, et al., 2003; World Health Organization and 
Health Action International[WHO and HAI], 2008;  Doloresco, et al., 2011). For
example, a recent study (Cameron et al., 2012) showed that up to 89% of drug cost 
2could be saved in the private health sector of low-to-medium income countries if 
lowest-priced generic equivalents of innovator brands are used. Similar cost saving
advantages from the use of generic medicines has been reported in high and middle-
income countries (Chan, 2011). For instance, in the USA, savings from the use of 
generics for the US healthcare system was around US$139.6 billion in 2009 (U.S. 
Department of Health and Human Services, 2010). In Europe, it has been estimated that 
generic medicines generate savings of more than €25 billion per annum (Simoens, 
2010). Likewise in Malaysia, a study by Shafie and Hassali (2008) estimated that 
consumers could potentially save up to 90% of the cost of their drugs by using generic 
products. In general, literature indicates that as more generic medicines become 
available, price competition in the off-patent pharmaceutical market ensues and the 
overall drug price falls (Caves, Whinston and Hurwitz, 1991; Reiffen and Ward, 2005; 
Saha, et al., 2006; Nguyen, Kaplan and Laing, 2008). Therefore, from the viewpoint of 
pharmaceutical cost containment and accessibility, it has been argued that “competition 
provided by generic medicines, is essential to keep public budgets under control and to 
maintain widespread access to medicines to the benefit of consumers” (European 
Commission [EC], 2009a, p.12).
However, in order to maximize the cost-saving benefits from generic medicines, their 
availability need to be ensured and sustained through prompt market entry following 
patent expiration of the innovator drug products (Kanavos, Costa-Font and Seeley, 
2008;  EC, 2009a; b; Sheppard, 2010). For instance, it was noted that: “efficient” and 
“timely” market entry of generic medicines ensures access to affordable medicines and 
3contributes significantly to the sustainability of the Australian Pharmaceutical Benefits 
Scheme (PBS) (Generic Medicines Industry Association, 2011). Conversely, substantial 
loss of savings could result if entry of generic medicines is delayed or hindered 
(Kesselheim, Fischer and Avorn, 2006; EC, 2009b). For example, European 
Commission in its study (EC, 2009b) that analysed the extent of post-patent entry of 
generic equivalents of top-selling prescription medicines in 27 member countries of the 
European Union between 2000 and 2007, estimated a loss of about €3 billion in savings 
for the European healthcare system as a result of delay in immediate entry of generic 
equivalents, following loss of patent and exclusivity of the innovator products. 
Furthermore, given the generic industry dependence on the development and production 
of  generic equivalents of  highly priced off-patent innovator products (Scott-Morton, 
2000; Prasnikar and Skerlj, 2006;  EC, 2009b; Borkowski, 2010), the ability to achieved 
entry in a prompt manner with less impediments, improves efficiency in the generic 
industry (Brundtland, 1999; United Nations Conference on Trade and Development-
International Centre for Trade and Sustainable Development [UNCTAD-ICTSD], 2005; 
Bianchi and Labory, 2006; Prasnikar and Skerlj, 2006; Lutz, Kemp and Dijkstra, 2010). 
This in turn result in benefits to the consumers and the health care system, as most drug 
expenditure are for drugs for which generic equivalents may not be available or 
insufficiently available to effect price-lowering competition (King and Kanavos, 2002; 
(Nguyen, Kaplan and Laing, 2008; Doloresco, et al., 2011). Thus, once generic 
equivalents of patent expired innovator products are available, the consumers and the 
healthcare payers can avail themselves of the resultant price advantages. As Bianchi and 
4Labory (2006, p.306 ) remarked, “promoting competition in the drug market has the 
main effect of promoting efficiency, but the resulting lower prices also improve access 
to medicines”. 
In summary, the availability and use of generic medicines provide opportunities for the 
containment of pharmaceutical costs and the sustenance of the health care system. But 
in order to derive the maximum benefits from generic medicines, their prompt entry 
following patent expiration of innovator products need to be ensured (Department of 
Health, UK, 2002; EC, 2009b; Iizuka, 2009). However, a number of interdependent 
factors influence the dynamics of post-patent entry of generic medicines in the 
pharmaceutical industry (Driouchi and Zouag, 2012). These factors, which are the 
primary subject of this research, and which will be given a detailed review in Chapter 2 
are pharmaceutical policy and regulatory environment; existence and strength of entry 
barriers; and the level of competition in the pharmaceutical market (Scott-Morton, 
1999, 2000; Hudson, 2000; Magazzini, Pammolli and Riccaboni, 2004; Competition 
Bureau, Canada, 2007; Kanavos, Costa-Font and Seeley, 2008; EC, 2009b; Brems, 
Seville and Baeyens, 2011).  
Meanwhile, given the intrinsic linkage between the healthcare system and the 
pharmaceutical industry (Homedes, Ugalde and Forns, 2005; Mukherjee, 2007), the 
following sections present an overview of the Malaysia healthcare system and 
pharmaceutical industry, and thus provide the background for the research problem. 
51. 2 Overview of the Malaysian Healthcare System
Malaysia is a developing country situated in the Southeast Asia region of the Asia 
continent. The country covers an area of about 330,290 square kilometres and has a 
total population (2010) of 28.25 million (Department of Statistics, Malaysia, 2011), 
with an annual population growth rate of 2.1% (MOH, Malaysia, 2010). Malaysia 
consists of two land masses separated by the South China Sea: West Malaysia 
(Peninsular Malaysia) and East Malaysia comprising of the Federal Territory Labuan, 
and States of Sabah and Sarawak (Figure 1).  Peninsular Malaysia has its frontiers with 
Thailand in the north and Singapore in the south, while Sabah and Sarawak borders the 
territory of Kalimantan, Indonesia (Department of Statistics, Malaysia, 2011).  Malaysia 
is made of five regions: the Northern region consisting the states of Perak, Penang, 
Kedah and Perlis; the Central region consisting the states of Kuala Lumpur, Selangor 
and Putrajaya; the Southern region consisting the states of Negeri Sembilan, Melaka 
and Johor; and the East coast region consisting the states of Pahang, Terengganu and 
Kelantan; and the East Malaysia region consisting the states of Sabah, Sarawak and 
Labuan (Tourism Malaysia, 2012).
6Figure 1.1 Geographical location of Malaysia (Hamidy, 2010)
Malaysia overall GDP (2010) was US$237.797 million (Ringgit Malaysia [RM] 
765.965 million) (Department of Statistics, Malaysia, 2011; United Nations, 2012) and 
GDP per capita (2010) was US$8.373 (United Nations, 2012). In 2009, the 
economically-productive population which consists of population aged 15 to 64 years 
was 18.0 million or 63.6% of the total population, while the economically dependent, 
that is aged below 15 years, and 65 years and above, was 10.3 million or 36.4% of the 
total population (MOH, Malaysia, 2009b). The three leading causes of deaths in the 
Malaysia public health sector in 2010 were diseases of the circulatory system (25.35%); 
diseases of the respiratory system (18.46%); and certain infectious and parasitic 
diseases (17.81%) (MOH, Malaysia, 2011a). While pregnancy, childbirth and the 
7puerperium (25.72%); diseases of the respiratory systems (9.56%); and injury, 
poisoning and other consequences of external causes (8.98%) constitutes the three 
leading causes of hospitalization (MOH, Malaysia, 2011a).
1.2.1 Structure of the Malaysian Healthcare System
The Malaysian healthcare system is divided into the public and private sectors. The 
public sector is government-led and provides healthcare services through hospitals, 
special medical institutions, and health clinics (Yu, Whynes and Sach, 2008; MOH, 
Malaysia, 2010). The private sector provides healthcare services through clinics, 
hospitals and medical centers (Yu, Whynes and Sach, 2008). The public health services 
are highly subsidized and funded by the government (Yu, Whynes and Sach, 2008; 
Rasiah, Abdullah and Tumin, 2011) primarily through general taxation, and from 
contributions to the employee provident fund (EPF) and the social security organization 
(SOSCO) (Ramesh, 2007; Yu, Whynes and Sach, 2008). The private sector health 
services are essentially fee-for-service system, where services are paid for out-of-pocket 
by patients or through private health insurance scheme (Yu, Whynes and Sach, 2006; 
Ramesh, 2007). In 2008, the total health expenditure in Malaysia was RM31.869 
billion, out of which government health expenditure was 44.1 % and the private health 
expenditure was 55.9 % (WHO, 2010a). The main source of financing for private health 
expenditure in Malaysia is out-of-pocket payments (73.2%), followed by private health 
insurance with 14.4% (WHO, 2010a). At present, there is no compulsory insurance or 
National Health Insurance scheme in Malaysia (MOH, Malaysia, 2008; Yu, Whynes
and Sach, 2011).
81.2.2 The Malaysian Pharmaceutical Industry
The Malaysian pharmaceutical industry is broadly categorized into three groups: the 
multinational pharmaceutical companies, domestic pharmaceutical manufacturing firms 
and generic pharmaceutical importers (Hassali, et al., 2009). Other players in the 
distributive sector of the industry are pharmaceutical wholesalers and retail pharmacies. 
The multinational pharmaceutical firms, which are represented by the Pharmaceutical 
Association of Malaysia (PhAMA) operate in Malaysia as subsidiaries or 
representatives of foreign research-based pharmaceutical manufacturers and are largely 
engaged in importation and distribution of branded innovative pharmaceutical products 
(Azmi and Alavi, 2001; Business Monitor International, 2010). The domestic 
pharmaceutical manufacturing industry, which is represented by the Malaysian 
Organization of Pharmaceutical Industries (MOPI), is mainly a generic pharmaceutical
formulating industry (Hassali, et al., 2009; Malaysian Industrial Development Authority 
[MIDA], 2009; Business Monitor International, 2010). 
As at 2011, there were 87 firms licensed to manufacture pharmaceuticals in Malaysia 
(Malaysian Organisation of Pharmaceutical Industries [MOPI], 2011). However, only a 
fraction of these firms are active local producers of prescription pharmaceuticals. For 
example, as at the end of 2007, only about 30 firms were licensed to manufacture 
prescription pharmaceuticals, while the rest produce over-the-counter medicines 
(Business Monitor International, 2010). Generic pharmaceuticals importers in Malaysia 
are very diverse and the players are not easily distinguishable. According to the 
Malaysian drug registration database, licensed importers of prescriptions 
9pharmaceuticals comprise of a mix of independent domestic companies, representatives 
of foreign-based firms and some licensed domestic manufacturers (National 
Pharmaceutical Control Bureau, Malaysia, 2010). The number of licensed community 
pharmacies in Malaysia as at 2009, were 2,047 (Pharmaceutical Services Division 
[PSD], Malaysia, 2009a). In Malaysia, the  Pharmaceutical distribution and supply 
follows the typical chain of distribution from the manufacturers to the final consumers 
via one to several intermediaries (Mustaffa and Potter, 2009), except in the public 
health sector where a concession firm procures and distributes drugs on the ‘approved 
products price list’ (APPL) to all government hospitals and clinics (Babar and Izham, 
2009; PSD, Malaysia, 2009a; Business Monitor International, 2010), while non-APPL 
drugs are obtained through Ministry of Health tender or by direct purchase (PSD, 
Malaysia, 2009a). 
The pharmaceutical industry in Malaysia is regulated by the National Pharmaceutical 
Control Bureau (NPCB) under the purview of the Drug Control Authority (DCA). 
Patent protection on pharmaceutical products and process in Malaysia is governed by 
the Patents Act 1983 (as amended) and the Patents Regulations 1986 (as amended) 
(Azmi, 2003); and these legislations are in compliant the World Trade Organization 
(WTO) agreement on trade-related intellectual property rights. (Gee, Azmi and Alavi, 
2009).
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1.3 Problem Statement 
Although the Malaysian healthcare system is generally seen as a ‘model’ for other 
developing countries in terms of overall health system performance (Smith, Correa and 
Oh, 2009), the rising healthcare expenditure in general, and pharmaceutical expenditure 
in particular has become increasingly challenging to the Malaysian government and 
consumers (MOH, Malaysia, 2005; Babar, et al., 2007; MOH, Malaysia, 2008; Babar 
and Izham, 2009; Smith, Correa and Oh, 2009; Yu, Whynes and Sach, 2011). For 
instance, the total expenditure on drug procurement for use in the government hospitals 
and clinics increased from RM 303.80 million in 1998 to RM 1510 million in 2008, 
representing a 397% change in pharmaceutical spending over a ten year period (PSD, 
Malaysia, 2008a). Furthermore, in 2009, the overall national pharmaceutical 
expenditure in Malaysia was around RM4.29 billion (14% of total health expenditure), 
with a substantial part accounted for by branded and patented drug products (Business 
Monitor International, 2010; Babar, Ibrahim and Hassali, 2011). For example in 2007, 
the total spending on the “top 150 drugs by expenditure” in Malaysia, was around 
RM2.18 billion (Faridah et al., 2010), many of which are newer prescription drug 
molecules for which generic equivalents may not be available (Babar, et al., 2007; 
Smith, Correa and Oh, 2009). 
This situation evidently has implications for drug affordability and accessibility, 
especially in the private sector where consumers have to pay for their medicines out-of-
pocket (Babar, et al., 2007; Shafie and Hassali, 2008; Business Monitor International, 
2010). Though, the local pharmaceutical industry has a strong capacity to manufacture 
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generic medicines (Hassali, et al., 2009, MIDA, 2009), the Malaysian pharmaceutical 
market continue to be dominated by patented and imported drugs (Azmi and Alavi, 
2001; Ministry of International Trade and Industry [MITI], Malaysia, 2006; Hassali, et 
al., 2009; Smith, Correa and Oh, 2009; Business Monitor International, 2010). For 
instance, in 2005, the Malaysian pharmaceutical market was estimated at RM 2.7 
billion, of which about 80% were accounted for by imported drugs (MITI, Malaysia, 
2006). Accordingly, the growth of domestic pharmaceutical industry is constrained 
(Azmi and Alavi, 2001; Tham and Yahya, 2008; Performance Management and
Delivery Unit [PEMANDU], Malaysia, 2010) and drug prices in Malaysia remain 
disproportionately high (Babar, et al., 2007; Babar and Izham, 2009; Smith, Correa and 
Oh, 2009), with a consequent rise in pharmaceutical expenditure. 
One factor that creates opportunity for drug affordability and containment of 
pharmaceutical expenditure is the ability for generic medicines producers to develop 
and make prompt market entry with generic equivalents of innovator product following 
patent expiration (Azmi and Alavi, 2001; Jaeger, 2006; Davies, 2008; EC, 2009b; 
Sheppard, 2010). Prompt and sufficient generic entry helps sustain the supply continuity 
of generic medicines, improves efficiency in the generic industry, and ensures the 
availability of affordable medicines and a consequent reduction of drug expenditure 
(Brundtland, 1999; UNCTAD-ICTSD, 2005; Bianchi and Labory, 2006; Jaeger, 2006; 
EC, 2009b; Brems, Seville and Baeyens, 2011; Doloresco, et al., 2011). However, in 
Malaysia, efficiency in the domestic generic industry remained a challenge (Shafie and
Hassali, 2008; PEMANDU, Malaysia, 2010) and high drug prices and escalating drug 
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expenditure has become burdensome (Babar et al., 2007; MOH, Malaysia, 2008; Babar 
and Izham, 2009; Smith, Correa and Oh, 2009), thus indicative of some impediments, 
structural or strategic to the development, prompt and sufficient market entry of generic 
medicines in Malaysia. 
Therefore, this study aims to explore the aforementioned problem and provide empirical 
evidence on the dimensions and dynamics of the post-patent entry of generic medicines 
in Malaysia, with a view to contribute to policy recommendations on the attenuation of 
pharmaceutical expenditure and improvement of the competitiveness of the generic 
medicines industry in Malaysia. 
1.4 Justification of Research 
In Malaysia, the introduction of highly priced new innovator medicines has become a 
major driver of the rising healthcare expenditure (MOH, Malaysia, 2008).  Hence, in the 
pursuit of drug affordability, pharmaceutical cost containment and improvement in the 
competitiveness of the generic industry,  the Malaysian government has put in place 
policies and regulatory measures aimed at encouraging the development, sufficient 
production of generic medicines and expedited market entry of newly off-patent drug 
products (MITI, Malaysia, 2006; MOH, Malaysia, 2009a). Additionally, the 
government viewed that “the anticipated expiry of several brand drugs, offers vast 
opportunity for the production of patent expired generic drugs, for both the local and 
export markets” (MITI, Malaysia, 2006, p. 413) and does not want “the introduction of 
generic drugs to be obstructed and delayed” (MOH, Malaysia, 2011b). 
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Yet, to date, little studies have been carried out on post-patent entry of generic 
medicines in Malaysia, particularly with respect to the phenomenon of patent expiration 
and the dynamics of entry of new generic medicines following patent expiration of 
innovator products. Conversely, some studies (De Run and Felix, 2006; Al-Gedadi, 
Hassali and Shafie, 2008; Babar and Awaisu, 2008; Thomas and Vitry, 2009; Chua, et 
al., 2010; Chong, et al., 2010a; b; 2011) have only looked at the knowledge, attitude and 
perception of practitioners and consumers on issues related to uptake of generic 
medicines in Malaysia. However, literature suggests that to fully understand the 
implications of pharmaceutical patents on introduction of generic medicines and 
pharmaceutical expenditure, studies on the generic entry process is crucial (Frank and
Salkever, 1992; EC, 2009b). Therefore, empirical studies on the dimensions and 
dynamics of the post-patent entry of generic medicines in Malaysia are needed to 
provide information to guide the policy objectives of the government. This is 
particularly important, given the strong patent protection system and proliferation of 
innovators’ pharmaceutical patents in Malaysia (Azmi and Alavi, 2001; Gee, Azmi and 
Alavi, 2009), with the propensity to impede entry of generic medicines and the 
likelihood of limiting drug affordability and accessibility (Correa, 2011). For instance, it 
has been reported that the highest number of patents granted in Malaysia between 1989 
and 2006 was to the pharmaceutical sector, with granted pharmaceutical patents 
described as having a “phenomenal” growth rate of 3,110% (Gee, Azmi and Alavi, 
2009, p. 332). Furthermore, over 90% of these patent applications and patent grants in 
Malaysia are foreign-owned (Gee, Azmi and Alavi, 2009; Smith, Correa and Oh, 2009; 
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Govindaraju and Wong, 2011). In view of this, Smith, Correa and Oh (2009, p. 689) 
remarked:
“Malaysia provides a good example of how patent protection can create 
inequalities in pharmaceutical trade between developed and developing 
countries; with developed countries exporting high-value patented drugs, and 
developing countries prevented from producing them, compelled to import 
them, with consequent issues for access to affordable medicines”.
Therefore, given the country’s health system reliance on the potential cost-lowering 
benefits of generic medicines and the generic industry dependence on expiration of 
patent on innovator products, with the opportunities for growth and pharmaceutical cost 
containment in the healthcare system, the availability of empirical information on post-
patent entry, its determinants and role of generic competition will be vital to the 
provision of policy recommendations and help contribute to government effort in 
pharmaceutical cost containment, ensuring access to affordable medicines and 
improving the competitiveness of the generic industry.
1.5 Research Objectives 
The general aim of this research was to study the dimensions and dynamics of the post-
patent entry of generic medicines in Malaysia, with a view to providing empirical 
evidence that is vital to generating informed policy decisions on containment of 
pharmaceutical expenditure and improvement in competitiveness of the Malaysia 
generic industry. To achieve this aim therefore, the following specific objectives were 
set forth:
15
1. To identify the existing policy and regulatory measures influencing the entry of 
generic medicines in Malaysia.
2. To explore the extent to which the identified policies and regulatory measures 
can potentially promote or impede the entry of generic medicines following 
patent expiration on innovator products in Malaysia.
3. To assess the factors influencing decisions to develop and introduce a new 
generic medicine into the Malaysian pharmaceutical market.
4. To identify the barriers to post-patent entry of generic medicines in Malaysia
5. To assess the views of Malaysian generic drug manufacturers on promotion of 
generic medicines in Malaysia.
6. To examine the pattern of generic entry into the Malaysian pharmaceutical 
market
7. To evaluate the time to entry of generic medicines into the Malaysian 
pharmaceutical market following patent expiration of innovator products in 
Malaysia.
8. To assess the potential effects of generic entry and competition on the prices of 
off-patent drug products in the Malaysian pharmaceutical market.
1.6 General Overview of Research Methodology
This section provides in brief, the methodologies utilized in this thesis. The detailed 
methods followed for each of the objectives were given in subsequent Chapters of the 
thesis. 
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In general, a combination of qualitative and quantitative methods were used to meet the 
research objectives and address the research questions (see Section 2.6) Mixed methods 
approach is commonly recommended in health policy and services research (O'Cathain, 
Murphy and Nicholl, 2007; Almarsdottir and Traulsen, 2009; Gilson, 2012; Mills, 
2012), as it broadens and deepens investigation of health policy and systems issues 
(Gilson, et al., 2011). Mixed research methods also served the purpose of 
“complementarity”, where each method addressed a different but overlapping aspect of 
the research objectives in order to achieve an “enriched, elaborated understanding of the 
phenomenon” under study (Greene, Caracelli and Graham, 1989; Smith, 2002; Gray, 
2009).
Research objectives 1 and 2, which were examined in Chapter 3 employed qualitative 
policy documents analysis and key informant survey.  Relevant key informants were 
surveyed through a combination of semi-structured interviews and structured self-
completed qualitative questionnaire. Data obtained were analysed using a deductive 
content analysis (Hsieh and Shannon, 2005; Elo and Kyngas, 2008).  A detailed 
description of the methodology and data analysis is provided in Chapter 3.
A cross-sectional mail survey approach was implemented to address the research 
objectives 3, 4 and 5. These objectives were examined in Chapter 4. The survey 
participants comprised of the members of the Malaysian Organization of 
Pharmaceutical Industries (MOPI). The questionnaire consisted of items on factors 
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influencing decisions to develop and introduce a new generic medicine into the 
Malaysian pharmaceutical market; entry barriers to new generic medicines into 
Malaysian pharmaceutical market; effectiveness of government regulations and policies 
in promoting generic medicines; satisfaction regarding the level of generic prescribing, 
dispensing, public awareness and education to healthcare professional about generic 
medicines in Malaysia. Data analysis included descriptive measures and inferential 
statistical tests. Detailed description of the methodology and data analysis is provided in 
Chapter 4.
Research objectives 6 and 7 examined in Chapter 5 utilized a dataset of ‘best-selling’ 
single entity prescription drug products in Malaysia that loss of basic patent protection 
and experienced generic entry between January 2001 and December 2009. Best-selling 
medicines were used on the basis of the empirical conclusion that entry of new generic 
medicines is predicted on the sales value of the drug molecule facing patent expiration 
(Bae, 1997; Hudson, 2000; Magazzini, Pammolli and Riccaboni, 2004; Saha, et al., 
2006; Iizuka, 2009). The basket of drugs for assessment was selected from 3 different 
sources in order to obtain a robust set of drug products with the highest market value 
(‘best-selling’). The characteristics and extent of generic entry were assessed using the 
following variables; therapeutic class of drug molecule; date of first marketing approval 
of innovator INN drug molecule; date of expiration of basic patent of innovator INN 
drug molecule; date of marketing approvals of all generics of the drug molecule; 
manufacturing sources of all generics of INN molecule i.e. local or imported; date of 
first generic entrants and number of generic entrants from January 2001-December 
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2009. Data were analysed descriptively and inferentially. Detailed description of the 
methodology and data analysis is provided in Chapter 5.
Research objective 8 was addressed through secondary analysis of the prices of off-
patent pharmaceutical products in Malaysia. Data were sourced from the results of 
national surveys on medicines prices in Malaysia. The retail price data of 28 
prescription off-patent multisource medicines collected in a national medicines price 
survey in Malaysia was utilized to examine the effects of generic competition as 
measured by the relationship between number of registered brands of the multisource 
medicines and their proportional prices. Detailed description of the methodology and 
data analysis is provided in Chapter 6.
1.7 Outline of the Research     
In examining the phenomenon pharmaceutical patent expiration and the entry of generic 
medicines in Malaysia, this research provides novel insights into the dynamics and 
determinants of post-patent entry of generic medicines in Malaysia; and the potential 
effects of generic competition in the Malaysian off-patent pharmaceutical market. 
Chapter 1 contained the introduction which sets out the context and scope of the 
research, provides background information on the Malaysian health systems and the 
importance of generic entry and availability in the pharmaceutical market. It announced 
the research problems and provided justifications for the study. Finally, it presents the 
research objectives to be addressed and outlines the methodology of the research. 
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Chapter 2 provided an extensive review of the extant literature on policies and 
regulatory measures influencing generic entry, the determinants and characteristics of 
entry and the effects of post-patent entry of generic medicines on pharmaceutical prices. 
Finally, it described the conceptual framework of the research. 
Chapter 3 examined the prevailing the policy and regulatory environment relating to 
generic medicines in Malaysia; and analyses the extent to which these policies can 
potentially promotes or hinders the entry of generic medicines following patent 
expiration of innovator drug products. The policy analysis is crucial and necessary to 
appreciate the entry determinants, characteristics, and potential effects of post-patent 
generic entry addressed in Chapters 4, 5 and 6 respectively. 
Chapter 4 provided an examination of the various determinants of market entry of 
generic medicines in Malaysia, from the perspective of the generic drug industry. The 
examined determinants range from issues related to the strategic behaviour of the 
innovator firms, pharmaceutical market characteristics, regulatory measures, and the 
demand-side drivers of generic entry.  
Chapter 5 characterized the pattern of post-patent entry of generic medicines in 
Malaysia and assessed the extent of generic entry in Malaysia, in terms of the speed of 
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entry following patent expiration and the number of entrants for a given patent-expired 
innovator drug products. 
Chapter 6 demonstrated the importance of prompt and sufficient entry and availability 
of generic medicines following patent expiration of innovator products in Malaysia by 
providing information on the potential effects of generic entry and competition on 
pharmaceutical prices in Malaysia.
Chapter 7 provided the summary of the major findings of this research along with 
conclusions reached regarding the thesis research questions. It then provided the 
limitations encountered in the research and suggestions for further studies. Finally, it 
presented the concluding remarks and outlined the research recommendations. 
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CHAPTER 2
LITERATURE REVIEW AND CONCEPTUAL FRAMEWORK
2.1 Introduction
This Chapter provides a detailed review of the extant literature relevant to the present 
research and presents the conceptual framework of the research issues mentioned in 
Chapter 1. The Chapter begins with an overview of generic medicines development 
process. Next, it discusses the extant literature on policies and regulatory framework 
impacting on post-patent entry of generic medicines; the determinants and 
characteristics of generic entry; and potential effects of post-patent entry of generic 
medicines on pharmaceutical prices.  Finally, it presents, on the basis of empirical 
evidence, the conceptual framework on post-patent entry and diffusion of generic 
medicines in the pharmaceutical market. A major focus of this Chapter is the provision 
of comprehensive background information that will subsequently guide the examination 
of the research objectives and research questions in Chapters 3, 4, 5 and 6.
2. 2 Overview of Generic Medicines Development Process
The entry of generic medicines following patent expiration of innovator drug product 
begins with the development of the generic drug entity (Prasnikar and Skerlj, 2006; 
Lionberger, 2008). This process is multifaceted, varied and sometimes overlaps, 
depending on the drug molecule and other regulatory requirements (Lionberger, 2008). 
However, for illustrative purpose, this thesis adopted the model proposed by Prasnikar 
and Skerlj (2006) (Figure 1).  
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The process of the development until market launch of a new generic product is 
classified into: Phases 0 (generation of idea), 1 (preliminary assessment), 2 (laboratory 
development), 3 (development of technology), 4 (registration) and 5 (launch) (Prasnikar 
and Skerlj, 2006). Phase 0 is the period of selection of the potential generic drug 
candidate worthy of development by the generic manufacturers.  
Figure 2.1 Schematic view of the development and market entry process of a new generic medicine 
Source: adapted from Prasnikar and Skerlj (2006) and Lionberger (2008)
Phase 1 represents the ‘desk research’ stage, where the manufacturer takes into 
consideration potential research and development commitments, manufacturing 
capabilities, regulatory and intellectual property concerns, marketing potentials and 
other commercial factors (Prasnikar and Skerlj, 2006). This phase also  include the 
collection of all relevant documentation about the potential drug molecule prior to 
initiation of any laboratory activities and identification of possible quality risks arising 
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from the active pharmaceutical ingredient prior to the development of a generic drug 
product (WHO, 2011). At phase 2, the manufacturer undertakes various preliminary 
laboratory tests depending on the nature and characteristics of the generic drug 
candidate. This includes selection and characterization of innovators comparator 
product, benchmarking for formulation experiments and stability studies, formulation 
selection experiments, pilot-bioequivalence and comparative dissolution studies and 
development of primary packaging (Prasnikar and Skerlj, 2006; WHO, 2011). Phase 3
is the development stage, when the drug formulation undergoes clinical studies, 
toxicological studies, bio-equivalent studies and completed stability studies. This phase 
ends with the production of registration batches (Prasnikar and Skerlj, 2006).  Phase 4
is the registration stage. At this phase the manufacturer files the product registration 
dossier with the drug regulatory authority for marketing authorization. The phase ends 
when the marketing authorization is issued by the authority (Prasnikar and Skerlj, 
2006). Phase 5 comprises of the pre-launch activities (e.g., production of the launch 
stock, ordering of raw materials, packaging materials etc.) and final market launch of 
the product (Prasnikar and Skerlj, 2006). In general, the above outlined process takes an 
average of 5 years (Prasnikar and Skerlj, 2006). For innovator products, the time taken 
from research and development, including filing for patent to market lunch is about 10 
years (EC, 2009b).
In brief, the process of generic drug development and entry comprises of pre-
development stage (phases 0 and 1) and development stage (Phases 2 and 3). Marketing 
authorization stage (Phase 4) and market entry stage (Phase 5).  However, the 
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development and the eventual market entry of generic pharmaceuticals are affected by a 
number of variables. These variables which are evidenced from previous work, are 
discussed in the following sections. 
2.3 Review of Literature 
The review of the related literature covers three broad areas. First, the known findings 
on the impact of pharmaceutical policies and regulatory measures on generic entry were 
discussed. Second, the large literature on the determinants and characteristics of post-
patent entry of generic medicines were discussed. Third, the literature findings on the 
effects of post-patent entry of generic medicines and potential contributions to 
pharmaceutical cost containment and competitiveness of the generic pharmaceutical 
market were provided.  
2.3.1 Generic Medicines Policies
In broad terms, generic medicines policies are pharmaceutical policies, including 
regulatory measures that are intended to promote the entry, availability and uptake of 
generic medicines in the pharmaceutical market (Hawkins, 2011). Although these 
policies are generally documented, however, like other health policies, generic 
medicines policies may include informal and unwritten practices of policy stakeholders 
and actors (Gilson, 2012). Policies related to generic medicines are highly diverse in 
nature with various policy measures implemented to meet the overall objectives of drug 
